Boehringer Inks Potential $2B Deal with Ribo, Targets NASH-MASH with siRNA Therapies
In a collaboration agreement announced Wednesday, Boehringer Ingelheim will gain access to Ribo’s platform to target hepatocytes with investigational siRNA therapies for nonalcoholic or metabolic dysfunction-associated steatohepatitis.